Evaluation of Remternetug (LY3372993) Versus Placebo in Early Alzheimer's Disease Patients at Risk for Cognitive and Functional Decline

The primary objective of this study is to evaluate the **time to clinically meaningful progression** in participants with early **Alzheimer's Disease**, as measured by the Clinical Dementia Rating (CDR) scale. This is clinically relevant as it aims to assess the efficacy of Remternetug in delaying cognitive and functional decline, which is a critical concern in the management of Alzheimer's Disease. The study involves a comparison between Remternetug and a placebo to determine the potential benefits of the investigational drug in slowing disease progression.

The clinical trial involves a total of **1394 participants** diagnosed with **Alzheimer's Disease**. The study population includes both male and female subjects, aged between **55 to 80 years**. Participants were selected based on specific criteria, including having a reliable study partner, a screening biomarker blood test indicating the presence of plaques in the brain, and experiencing no or only mild problems with memory and function. The trial does not include a vulnerable population. Lifestyle considerations such as diet, physical activity, or habits were not specified in the available data. The selection process ensures that participants meet the necessary health status requirements to evaluate the time to clinically meaningful progression as measured by the Clinical Dementia Rating (CDR).

The clinical trial is designed to evaluate the efficacy and safety of **Remternetug** compared to a placebo in participants with early **Alzheimer's Disease**. This is a Phase III, randomized, double-blind, placebo-controlled study. The trial aims to assess the time to clinically meaningful progression as measured by the Clinical Dementia Rate (CDR), a clinician-rated scale that evaluates the participant's stage and degree of impairment. The estimated duration of the trial is from March 2025 to January 2031, with participant involvement expected to last up to one year.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on criteria such as age (55 to 80 years), the presence of a reliable study partner, a screening biomarker blood test indicating brain plaques, and having no or only mild memory and functional problems. Following successful screening, participants will be randomized to receive either Remternetug or a placebo, both administered as a **solution for injection**. The study will include regular follow-up visits to monitor safety, efficacy, and any adverse events. The end-of-study visit will conclude the participant's involvement, assessing the final outcomes and collecting data for analysis.

Participants may be withdrawn from the study early if they experience significant adverse effects, fail to comply with study procedures, or if the investigator deems it necessary for their safety. The trial is not categorized as low intervention, as it involves a non-authorized investigational medicinal product. The study is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial involves the administration of **Remternetug**, an experimental medication, which is a **solution for injection**. The active substance in Remternetug is identified as LY3372993, a protein-based compound. The pharmaceutical form is a solution intended for injection, and it is manufactured by Eli Lilly and Company Limited. The administration route is via injection, although specific dosing schedules and frequency of administration are not detailed in the provided data. The trial does not specify a maximum daily or total dose, and the treatment period is limited to one time unit, as per the trial's design.

In addition to the experimental treatment, a **placebo** is used as a comparator in the study. The placebo is designed to match the appearance and administration form of Remternetug, ensuring blinding in the trial. The placebo does not contain any active substance and is administered in the same manner as the experimental drug, maintaining consistency in the trial protocol. The placebo's pharmaceutical form and administration route are not explicitly detailed, but it is implied to be similar to that of Remternetug to ensure effective blinding.

Efficacy in the clinical trial titled "J1G-MC-LAKI: A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline" will be assessed using the primary endpoint of time to clinically meaningful progression as measured by the **Clinical Dementia Rating (CDR)**. The CDR is a clinician-rated scale that provides an overall assessment of the participant's stage and degree of impairment across the continuum of early Alzheimer's Disease. This scale will be utilized to determine the efficacy of the investigational product, Remternetug, compared to a placebo. The trial aims to evaluate the time it takes for participants to reach a clinically meaningful progression in their condition, as indicated by changes in their CDR scores. The trial is designed to confirm the safety and efficacy of Remternetug in a Phase III setting, focusing on participants who are at risk for cognitive and functional decline due to early Alzheimer's Disease.